10-K: Starry Sea Acquisition Corp. Reports 2025 Net Income, Eyes China Health Sector Deal

Starry Sea Acquisition Corp., a blank check company, reported a net income of $320,643 for fiscal year 2025 and announced a Letter of Intent to acquire Forever Young International Limited, a China-based health industry operator.

Summary

• Starry Sea Acquisition Corp. (SSEA) is a Special Purpose Acquisition Company (SPAC) incorporated on December 5, 2024, with no operating history or revenues to date.
• The company completed its Initial Public Offering (IPO) on August 11, 2025, selling 5,750,000 units at $10.00 per unit, generating gross proceeds of $57,500,000.
• Each unit consists of one ordinary share and one right to receive one-sixth (1/6th) of an ordinary share upon business combination.
• Simultaneously with the IPO, 247,121 private units were sold to the sponsor for $2,471,210.
• A total of $57,500,000 from the IPO and private placement proceeds was placed in a U.S.-based trust account.
• For the fiscal year ended December 31, 2025, the company reported a net income of $320,643, primarily from $863,257 in interest earned on the trust account, offset by $542,614 in formation and operating costs.
• As of December 31, 2025, the company had $112,134 in cash and cash equivalents outside the trust account and a working capital of $379,066.
• On September 29, 2025, the company entered into a Letter of Intent (LOI) with Forever Young International Limited, a Cayman Islands exempted company operating in China's health industry, for a proposed business combination.
• The LOI contemplates a pre-money equity value for Forever Young in the range of approximately $750 million to $900 million, with consideration expected to be rollover equity in the form of ordinary shares of the post-closing entity, valued at $10 per share.
• The company has 15 months from August 7, 2025, to complete an initial business combination.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing with a neutral-to-slightly positive sentiment. While the company has successfully completed its IPO and identified a potential target, the inherent risks of SPACs, particularly those with significant ties to China and the associated regulatory uncertainties, temper enthusiasm. The LOI is a positive step, but it is not a definitive agreement, and the going concern warning is standard for a SPAC at this stage.

Positives

• Successfully completed its Initial Public Offering (IPO) and private placement, raising $57,500,000 for the trust account.
• Reported a net income of $320,643 for the fiscal year ended December 31, 2025, driven by interest earned on the trust account.
• Entered into a Letter of Intent for a proposed business combination with Forever Young International Limited, a health industry operator in China, indicating progress in identifying a target.
• The proposed target, Forever Young, has a significant pre-money equity value range of $750 million to $900 million, suggesting a substantial acquisition opportunity.

Negatives

• The independent registered public accounting firm's report expresses substantial doubt about the company's ability to continue as a going concern due to no operating history or revenues.
• The company has a limited timeframe of 15 months from August 7, 2025, to complete a business combination, after which it would liquidate.
• Public shareholders face significant dilution from founder shares acquired at a nominal price ($0.017 per share) and potential future equity issuances.
• The company's officers and directors have significant ties to China, which may limit the pool of non-PRC target companies and expose the company to various legal and operational risks associated with operating in China.
• Potential conflicts of interest exist due to officers and directors having pre-existing fiduciary and contractual obligations to other entities, including other SPACs.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to no operating history or revenues.
• Failure to complete a business combination within 15 months from August 7, 2025, would lead to liquidation, and public shareholders may only receive $10.00 per share or less, with rights expiring worthless.
• The ability of a large number of shareholders to exercise redemption rights may prevent the company from consummating the most desirable business combination or optimizing its capital structure.
• Intense competition in finding an attractive target for an initial business combination could increase costs or result in inability to find a suitable target.
• Potential U.S. foreign investment regulations (CFIUS review) if the proposed business combination is with a U.S. target company, given the sponsor's and management's ties to the PRC.
• Issuance of additional ordinary or preferred shares or debt securities to complete a business combination could significantly reduce the equity interest of current shareholders and cause a change in control.
• Third parties may bring claims against the company, potentially reducing the proceeds held in the trust account and the per-share redemption price.
• Shareholders may be held liable for claims by third parties against the company to the extent of distributions received by them if the company enters insolvent liquidation.
• Nasdaq may delist the company's securities, limiting liquidity and trading ability.
• The company's lack of business diversification means its success will be entirely dependent on the future performance of a single business.
• Management's flexibility in selecting an acquisition candidate and their financial interest in consummating a business combination may lead to decisions not in the best interest of all shareholders.
• Significant legal and operational risks associated with acquiring and operating a target business with primary operations in China, including regulatory oversight by the PRC government, data security, and antitrust laws.
• Uncertainty regarding the interpretation and enforcement of PRC laws and regulations, which could limit legal protections and affect business operations.
• Governmental control of currency conversion in China may restrict the ability to remit foreign currency for dividends or capital contributions.
• U.S. laws like the HFCAA and AHFCAA may impact trading in securities and restrict the ability to complete a business combination with certain China-based companies if their auditors are not subject to PCAOB inspections.

Future Outlook

The company's future outlook is entirely dependent on successfully completing its initial business combination within 15 months from August 7, 2025. It intends to leverage its management team's expertise and networks to identify and acquire a target with compelling economics, a defensible market position, and growth opportunities, potentially benefiting from a U.S. public listing. The Letter of Intent with Forever Young International Limited represents a significant step towards this goal, with an anticipated pre-money equity value of $750 million to $900 million.

Management Comments

• Management believes that the company's structure will make it an attractive business combination partner, offering an alternative to a traditional Initial Public Offering that is less expensive and offers greater certainty of execution.
• Management intends to use substantially all of the funds held in the trust account, including any interest earned, to complete the initial business combination.
• Management believes that the company does not need additional capital to satisfy its liquidity needs beyond the net proceeds from the IPO and funds held outside the Trust Account for existing payables and business combination search activities.

Industry Context

StockSavvy.ai notes that Starry Sea Acquisition Corp. operates within the highly competitive SPAC market, which has seen significant activity in recent years. The company's strategy to target a business in the health industry, particularly one with operations in China, aligns with broader trends of SPACs seeking growth opportunities in specialized sectors and emerging markets. However, the strong competition among SPACs for attractive targets, coupled with increasing regulatory scrutiny on U.S.-listed Chinese companies, presents notable challenges. The proposed acquisition of Forever Young International Limited, a health industry operator in China, positions the company to potentially capitalize on the growing healthcare market in the PRC, but also exposes it to the unique geopolitical and regulatory risks detailed in the filing, which could deter some investors or make deal completion more complex compared to a purely domestic transaction.

Comparison to Industry Standards

• The company's structure as a SPAC with a 15-month deadline to complete a business combination is standard for many SPACs, though some may have longer or shorter periods.
• The requirement for a target business to have a fair market value of at least 80% of the trust account balance is a common Nasdaq listing rule for SPACs.
• The dilution experienced by public shareholders (~98.1%) due to founder shares acquired at a nominal price is typical for SPACs, where sponsors take significant equity for minimal investment.
• The expression of 'substantial doubt about the ability to continue as a going concern' is a standard disclosure for SPACs that have no operations or revenues and rely on IPO proceeds and future business combinations for viability.
• The company's election not to opt out of the extended transition period for complying with new or revised financial accounting standards, as an emerging growth company, is a common practice among smaller public entities, but may make financial statement comparisons with non-emerging growth companies difficult.

Management Changes

Corporate Governance

Legal Proceedings

• No material litigation, arbitration, or governmental proceeding currently pending against the company or any members of its management team as of December 31, 2025.

Related Party Transactions

• The sponsor purchased 1,437,500 founder shares for an aggregate price of $25,000, or approximately $0.017 per share.
• 205,000 founder shares were transferred from the sponsor to two executive officers and three independent director nominees at nil consideration.
• The sponsor receives a monthly fee of $10,000 for office space, utilities, and administrative support services, commencing August 11, 2025, until the earlier of business combination completion or liquidation.
• The sponsor loaned the company up to $500,000 via an unsecured, interest-free promissory note, which was repaid in full upon the IPO closing ($387,484 drawn down).
• Officers and directors, or their affiliates, may loan funds to the company to finance transaction costs for an initial business combination, to be repaid upon closing of the business combination without interest.
• The holders of founder shares and private units are entitled to registration rights for resale of their securities.

Stakeholder Impact

• Shareholders: Potential for significant returns if a successful business combination is completed, but also face substantial dilution and risks associated with the SPAC structure and potential target's jurisdiction. Public shareholders have redemption rights under certain conditions.
• Employees (Executive Officers and Directors): Receive founder shares (some at nil consideration) and are reimbursed for out-of-pocket expenses. May negotiate employment/consulting agreements with the combined company post-business combination. Subject to Code of Conduct and Ethics and a Compensation Recovery Policy.
• Customers/Suppliers (of potential target): The proposed business combination with Forever Young, a health industry operator in China, could impact its existing customer and supplier relationships depending on the integration and strategic direction of the combined entity.
• Creditors: Claims of creditors could take priority over public shareholders' claims on the trust account in the event of liquidation, potentially reducing the per-share redemption price.

Next Steps

• Negotiate and finalize a definitive agreement for the proposed business combination with Forever Young International Limited.
• Conduct confirmatory due diligence on Forever Young International Limited.
• Seek shareholder approval for the initial business combination, if required by law or Nasdaq rules.
• Complete the initial business combination within 15 months from August 7, 2025.
• Continue to identify and evaluate alternative target businesses if the proposed combination with Forever Young does not materialize.

Key Dates

Keywords

SPAC, Blank Check Company, Merger, Acquisition, Business Combination, SEC Filing, 10-K, Financial Report, Trust Account, IPO, Nasdaq, Corporate Governance, Risk Factors, China, Health Industry, Forever Young International Limited, Cayman Islands, Securities Exchange Act, Financial Performance, Going Concern, Dilution, Regulatory Risk, CFIUS, PRC Regulations, Cybersecurity, HFCAA, Clawback Policy